ROQAF
Price
$0.02
Change
-$0.03 (-60.00%)
Updated
Jul 14 closing price
Capitalization
3.83M
Intraday BUY SELL Signals
SKYE
Price
$1.31
Change
-$0.02 (-1.50%)
Updated
Nov 19 closing price
Capitalization
42.64M
Intraday BUY SELL Signals
Interact to see
Advertisement

ROQAF vs SKYE

Header iconROQAF vs SKYE Comparison
Open Charts ROQAF vs SKYEBanner chart's image
Roquefort Therapeutics
Price$0.02
Change-$0.03 (-60.00%)
Volume$1K
Capitalization3.83M
Skye Bioscience
Price$1.31
Change-$0.02 (-1.50%)
Volume$133.5K
Capitalization42.64M
ROQAF vs SKYE Comparison Chart in %
SKYE
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ROQAF vs. SKYE commentary
Nov 20, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ROQAF is a Hold and SKYE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 20, 2025
Stock price -- (ROQAF: $0.02 vs. SKYE: $1.33)
Brand notoriety: ROQAF and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ROQAF: 100% vs. SKYE: 13%
Market capitalization -- ROQAF: $3.83M vs. SKYE: $42.64M
ROQAF [@Biotechnology] is valued at $3.83M. SKYE’s [@Biotechnology] market capitalization is $42.64M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.82B to $0. The average market capitalization across the [@Biotechnology] industry is $2.12B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ROQAF’s FA Score shows that 1 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • ROQAF’s FA Score: 1 green, 4 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, both ROQAF and SKYE are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SKYE’s TA Score shows that 5 TA indicator(s) are bullish.

  • SKYE’s TA Score: 5 bullish, 3 bearish.

Price Growth

ROQAF (@Biotechnology) experienced а 0.00% price change this week, while SKYE (@Biotechnology) price change was -12.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.19%. For the same industry, the average monthly price growth was -5.74%, and the average quarterly price growth was +63.93%.

Industries' Descriptions

@Biotechnology (-2.19% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SKYE($42.6M) has a higher market cap than ROQAF($3.83M). SKYE YTD gains are higher at: -53.004 vs. ROQAF (-57.300).
ROQAFSKYEROQAF / SKYE
Capitalization3.83M42.6M9%
EBITDAN/A-41.68M-
Gain YTD-57.300-53.004108%
P/E RatioN/A3.57-
RevenueN/A0-
Total CashN/A48.6M-
Total DebtN/A368K-
FUNDAMENTALS RATINGS
SKYE: Fundamental Ratings
SKYE
OUTLOOK RATING
1..100
81
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
96
PRICE GROWTH RATING
1..100
91
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SKYE
RSI
ODDS (%)
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
85%
Momentum
ODDS (%)
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
87%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
89%
Aroon
ODDS (%)
N/A
View a ticker or compare two or three
Interact to see
Advertisement
SKYE
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WIP38.79-0.08
-0.21%
SPDR® FTSE Intl Govt Infl-Protd Bd ETF
XTWY38.71-0.09
-0.24%
BondBloxx Bloomberg TwentyYrTrgDuUSTrETF
QQJG26.49-0.12
-0.45%
Invesco ESG NASDAQ Next Gen 100 ETF
ICF60.11-0.51
-0.83%
iShares Select U.S. REIT ETF
SPMC15.07-0.50
-3.21%
Sound Point Meridian Capital, Inc.

ROQAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ROQAF has been loosely correlated with GNTA. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ROQAF jumps, then GNTA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ROQAF
1D Price
Change %
ROQAF100%
N/A
GNTA - ROQAF
36%
Loosely correlated
-10.05%
CRBP - ROQAF
22%
Poorly correlated
-1.79%
SVRA - ROQAF
21%
Poorly correlated
+10.31%
SKYE - ROQAF
21%
Poorly correlated
N/A
SNTI - ROQAF
6%
Poorly correlated
+2.75%
More